Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, PRELUDE THERAPEUTICS INC reported revenue of $12M, up 73.4% year over year. Operating margin was -861.3% and net margin -819.6%, on a free-cash-flow margin of -464.3% with capital expenditure at 0.6% of revenue. Every figure is computed directly from PRLD's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $12M | -861.3% | -819.6% |
| FY2024 | $7M | -1995.9% | -1816.8% |
| FY2023 | n/a | n/a | n/a |
| FY2022 | n/a | n/a | n/a |
| FY2021 | n/a | n/a | n/a |
How does PRLD compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.